表纸
市场调查报告书

消化道相关的各种合作契约:契约条件·协定内容

Global Gastrointestinal Partnering 2014-2020: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品编码 250304
出版日期 内容资讯 英文 300+ Pages
商品交期: 最快1-2个工作天内
价格
消化道相关的各种合作契约:契约条件·协定内容 Global Gastrointestinal Partnering 2014-2020: Deal trends, players and financials
出版日期: 2020年10月01日内容资讯: 英文 300+ Pages
简介

本报告提供消化道相关的各种合作契约相关调查分析,近年来的各种契约趋势,大规模契约及大医药品经营者的契约概要,契约区分·现开发阶段·技术区分·各种类适应症的名录等汇整资料,为您概述为以下内容。

摘要整理

第1章 简介

第2章 消化道相关的各种契约趋势

  • 简介
  • 过去数年的消化道相关的合作
  • 大制药公司的契约活动
  • 对消化道相关产业不积极的大型制药公司
  • 消化道相关的合作:各类型契约
  • 消化道相关的合作:各产品部门
  • 消化道相关的合作:各开发阶段
  • 消化道相关的合作:各技术类型
  • 消化道相关的合作:各适应症
  • 平均契约期间

第3章 主要契约

  • 简介
  • 主要契约:各交易金额
  • 大型制药公司有关的主要契约

第4章 大制药公司的契约

  • 简介
  • 大制药公司的合作契约的利用法
  • 企业简介

第5章 契约名录

  • 简介
  • 各类型契约
    • 资产购买
    • 大的对外授权
    • 共同开发
    • 共同R&D
    • 共同贩卖
    • 服务契约
    • 共同促销
    • 开发
    • 流通
    • 股票购买
    • 授权
    • 诉讼
    • 贷款
    • 制造
    • 行销
    • 选择
    • 推销
    • 研究
    • 和解相关
    • 辅助许可证
    • 供给
    • 技术转移
    • 结束
  • 各开发阶段
    • 药物发明
    • 制剂设计
    • 上市
    • 阶段I
    • 阶段II
    • 阶段III
    • 前临床
    • 法规
  • 各技术类型
    • 抗体
    • 生物学的化合物
    • 细胞治疗
    • 设备
    • 诊断
    • 药物开发工具
    • 给药
    • 实现技术
    • 设备
    • 设备
    • 基因学
    • 成像
    • 天然产品
    • 寡核苷酸
    • 胜肽
    • 蛋白质体学
    • 研究服务
    • 研究支援
    • 筛检
    • 小分子
    • 软件工具
    • 干细胞

第6章 消化道相关的契约:各适应症

  • 简介
  • 各适应症
    • 消化道
    • 阑尾炎
    • 麸质过敏症
    • 食道逆流
    • 食道炎
    • 胃炎
    • 肠胃炎
    • 痔(痔核)
    • 疝气
    • 发炎性肠道疾病
    • 克隆氏症
    • 溃疡性大肠炎
    • 大肠躁鬱症
    • 吸收不良
    • 营养不良
    • 胰炎
    • 消化性溃疡
    • 胃溃疡
    • 腹痛
    • 腹水
    • 排便
    • 便秘
    • 腹泻
    • 消化不良
    • 吞咽障碍
    • 黄疸
    • 呕吐

第7章 合作机会

  • 网路伙伴合作
  • 合作伙伴活动
  • 相关资料

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: CP2214

The Global Gastrointestinal Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies

Global Gastrointestinal Partnering 2014 to 2020 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Gastrointestinal partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Gastrointestinal partnering agreement structure

Gastrointestinal partnering contract documents

Top Gastrointestinal deals by value

Most active Gastrointestinal dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.

The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gastrointestinal deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gastrointestinal deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2014. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.

Report scope

Global Gastrointestinal Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.

Global Gastrointestinal Partnering 2014 to 2020 includes:

  • Trends in Gastrointestinal dealmaking in the biopharma industry since 2014
  • Analysis of Gastrointestinal deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Gastrointestinal deal contract documents
  • Comprehensive access to over 420 Gastrointestinal deal records
  • The leading Gastrointestinal deals by value since 2014
  • Most active Gastrointestinal dealmakers since 2014
  • The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.

In Global Gastrointestinal Partnering 2014 to 2020, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gastrointestinal Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 420 gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Gastrointestinal Partnering 2014 to 2020 provides the reader with the following key benefits:

  • In-depth understanding of Gastrointestinal deal trends since 2014
  • Access Gastrointestinal deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Gastrointestinal partner companies
  • Comprehensive access to over 420 links to actual Gastrointestinal deals entered into by the world's biopharma companies
  • Indepth review of Gastrointestinal deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Gastrointestinal opportunities
  • Uncover companies actively partnering Gastrointestinal opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gastrointestinal dealmaking

  • 2.1. Introduction
  • 2.2. Gastrointestinal partnering over the years
  • 2.3. Gastrointestinal partnering by deal type
  • 2.4. Gastrointestinal partnering by industry sector
  • 2.5. Gastrointestinal partnering by stage of development
  • 2.6. Gastrointestinal partnering by technology type
  • 2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 -Financial deal terms for Gastrointestinal partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Gastrointestinal partnering
  • 3.3. Gastrointestinal partnering headline values
  • 3.4. Gastrointestinal deal upfront payments
  • 3.5. Gastrointestinal deal milestone payments
  • 3.6. Gastrointestinal royalty rates

Chapter 4 - Leading Gastrointestinal deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Gastrointestinal partnering
  • 4.3. List of most active dealmakers in Gastrointestinal
  • 4.4. Top Gastrointestinal deals by value

Chapter 5 - Gastrointestinal contract document directory

  • 5.1. Introduction
  • 5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Gastrointestinal therapeutic target

Appendices

  • Appendix 1 - Directory of Gastrointestinal deals by company A-Z 2014 to 2020
  • Appendix 2 - Directory of Gastrointestinal deals by deal type 2014 to 2020
  • Appendix 3 - Directory of Gastrointestinal deals by stage of development 2014 to 2020
  • Appendix 4 - Directory of Gastrointestinal deals by technology type 2014 to 2020
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering
  • Table of figures
  • Figure 1: Gastrointestinal partnering since 2014
  • Figure 2: Gastrointestinal partnering by deal type since 2014
  • Figure 3: Gastrointestinal partnering by industry sector since 2014
  • Figure 4: Gastrointestinal partnering by stage of development since 2014
  • Figure 5: Gastrointestinal partnering by technology type since 2014
  • Figure 6: Gastrointestinal partnering by indication since 2014
  • Figure 7: Gastrointestinal deals with a headline value
  • Figure 8: Gastrointestinal deals with upfront payment values
  • Figure 9: Gastrointestinal deals with milestone payment
  • Figure 10: Gastrointestinal deals with royalty rates
  • Figure 11: Active Gastrointestinal dealmaking activity- 2014 to 2020
  • Figure 12: Top Gastrointestinal deals by value since 2014